Mismatch repair-deficient status associates with favorable prognosis of Eastern Chinese population with sporadic colorectal cancer

Gong,Qing; Zhang,Huan‑Hu; Sun,Sheng‑Bo; Ge,Wen‑Min; Li,Yue; Zhu,Yong‑Cun; Li,Le‑Ping

doi:10.3892/ol.2018.8192

Mismatch repair-deficient status associates with favorable prognosis of Eastern Chinese population with sporadic colorectal cancer

Authors:
- Qing Gong
- Huan‑Hu Zhang
- Sheng‑Bo Sun
- Wen‑Min Ge
- Yue Li
- Yong‑Cun Zhu
- Le‑Ping Li
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Gastrointestinal Surgery, Weihai Municipal Hospital, Binzhou Medical University, Weihai, Shandong 264200, P.R. China, Department of Pathology, Weihai Municipal Hospital, Binzhou Medical University, Weihai, Shandong 264200, P.R. China, Department of Gynecology, Weihai Municipal Hospital, Binzhou Medical University, Weihai, Shandong 264200, P.R. China
Published online on: March 7, 2018 https://doi.org/10.3892/ol.2018.8192
Pages: 7007-7013
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression level of DNA mismatch repair gene (MMR) in in sporadic colorectal cancer (SCRC) in eastern China, and to investigate the association between MMR status and prognosis of patients with SCRC. Patient archives from the Department of Gastrointestinal Surgery of Weihai Municipal Hospital (Weihai, China) were retrospectively collected between January 2011 and January 2012. Of the 221 consecutive patients identified, 192 patients who met the criterion were deemed eligible for inclusion. Immunohistochemistry (IHC) was conducted to detect the expression of MMR proteins MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MSH6 and PMS1 homolog 2, mismatch repair system component (PMS2) expression and mutation in sporadic colorectal cancer (SCRC). Kaplan‑Meier plots and log‑rank tests were performed to conduct survival analysis and Cox proportional hazard regression models were conducted to determine independent prognostic factors. The total rate of deficient MMR (dMMR) was 14.58% (28/192): MSH6, 0.52% (1/192); PMS2, 4.17% (8/192); MSH2/MSH6, 3.65% (7/192); and MLH1/PMS2, 6.25% (12/192). The dMMR group had a significantly longer overall survival time compared with proficient MMR (pMMR) group (P=0.017). Disease‑free survival time of dMMR group was also longer than pMMR group (P=0.027). Multivariate analysis using the Cox regression model confirmed that MMR status was an independent prognostic factor for SCRC. Loss of MMR expression was indicative of a favorable outcome for patients with SCRC, and MMR status could be viewed as an independent prognostic factor.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zheng R, Zeng H, Zhang S and Chen W: Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 36:662017. View Article : Google Scholar : PubMed/NCBI
3	Markowitz SD and Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kawakami H, Zaanan A and Sinicrope FA: Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol. 6:676–684. 2015.PubMed/NCBI
5	Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
6	Worthley DL, Whitehall VL, Spring KJ and Leggett BA: Colorectal carcinogenesis: Road maps to cancer. World J Gastroenterol. 13:3784–3791. 2007. View Article : Google Scholar : PubMed/NCBI
7	Sameer AS, Nissar S and Fatima K: Mismatch repair pathway: Molecules, functions and role in colorectal carcinogenesis. Eur J Cancer Prev. 23:246–257. 2014. View Article : Google Scholar : PubMed/NCBI
8	Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A and Akewanlop C: Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. World J Gastroenterol. 21:926–934. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 20:1043–1048. 2002. View Article : Google Scholar : PubMed/NCBI
10	Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 95:6870–6875. 1998. View Article : Google Scholar : PubMed/NCBI
11	Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
12	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
13	Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al: Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
14	Compton CC and Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 54:295–308. 2004. View Article : Google Scholar : PubMed/NCBI
15	Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, et al: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 124:979–994. 2000.PubMed/NCBI
16	Wang LG, Ni Y, Su BH, Mu XR, Shen HC and Du JJ: MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol. 42:957–962. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ma H, Wang L, Zhang T, Shen H and Du J: Loss of β-arrestin1 expression predicts unfavorable prognosis for non-small cell lung cancer patients. Tumour Biol. 37:1341–1347. 2016. View Article : Google Scholar : PubMed/NCBI
18	Bhattacharya P and McHugh TW: Lynch SyndromeStatPearls. StatPearls Publishing StatPearls Publishing LLC Treasure Island (FL); 2017
19	Kawakami H, Zaanan A and Sinicrope FA: Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 16:302015. View Article : Google Scholar : PubMed/NCBI
20	Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG, Winship I, et al: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. J Clin Oncol. 30:958–964. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sheng JQ, Chan TL, Chan YW, Huang JS, Chen JG, Zhang MZ, Guo XL, Mu H, Chan AS, Li SR, et al: Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer. Chin J Dig Dis. 7:197–205. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ericson K, Halvarsson B, Nagel J, Rambech E, Planck M, Piotrowska Z, Olsson H and Nilbert M: Defective mismatch-repair in patients with multiple primary tumours including colorectal cancer. Eur J Cancer. 39:240–248. 2003. View Article : Google Scholar : PubMed/NCBI
23	Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525–4530. 1995.PubMed/NCBI
24	Belvederesi L, Bianchi F, Galizia E, Loretelli C, Bracci R, Catalani R, Amati M and Cellerino R: MSH2 missense mutations and HNPCC syndrome: Pathogenicity assessment in a human expression system. Hum Mutat. 29:E296–E309. 2008. View Article : Google Scholar : PubMed/NCBI
25	Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, et al: Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 11:8332–8340. 2005. View Article : Google Scholar : PubMed/NCBI
26	Ohrling K, Edler D, Hallström M and Ragnhammar P: Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer. Acta Oncol. 49:797–804. 2010. View Article : Google Scholar : PubMed/NCBI
27	Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J, et al: Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 33:126–133. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, et al: Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 29:1261–1270. 2011. View Article : Google Scholar : PubMed/NCBI
29	Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
30	Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011. View Article : Google Scholar : PubMed/NCBI
31	Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA and Joensuu H: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 119:921–928. 2000. View Article : Google Scholar : PubMed/NCBI
32	Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N and Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 355:1745–1750. 2000. View Article : Google Scholar : PubMed/NCBI
33	Sinicrope FA and Yang ZJ: Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol. 7:467–474. 2011. View Article : Google Scholar : PubMed/NCBI
34	Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, et al: NCCN Guidelines Insights: Prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw. 14:509–519. 2016. View Article : Google Scholar : PubMed/NCBI
35	Engstrom PF, Arnoletti JP, Benson AB III, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, et al: NCCN clinical practice guidelines in oncology: Colon cancer. J Natl Compr Canc Netw. 7:778–831. 2009. View Article : Google Scholar : PubMed/NCBI
36	Benson AB III, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, et al: Colon cancer, version 3.2014. J Natl Compr Canc Netw. 12:1028–1059. 2014. View Article : Google Scholar : PubMed/NCBI